| Symbol | FBSBF |
|---|---|
| Name | 4BASEBIO PLC |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | CB24 5QE United Kingdom ENG 25 Norman Way, Over |
| Telephone | +44 (0) 1223 967943 |
| Fax | — |
| — | |
| Website | https://www.4basebio.com/ |
| Incorporation | GB |
| Incorporated On | 1997 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: LSE - London Stock Exchange |
| CIK | — |
| Description | 4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5 and 3 ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccines and therapeutics; and oeDNA, or open ended DNA, a linear, double stranded DNA product ideal for genome editing. It also provides osDNA, or open stabilized DNA, a product incorporating nucleotide modifications within the DNA backbone enables tuning of the immunostimulatory properties of the construct for DNA vaccine applications; and The Hermes, a proprietary delivery platform for nucleic acid and protein payloads appears to offer a thermo-stable alternative to traditional lipid based delivery systems. Additional info from OTC: |
No news found.